Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Submitted by
admin
on January 14, 2025 - 11:07am
Source:
CNBC
News Tags:
Eli Lilly
earnings
Headline:
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
snippet:
Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations.
Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment Mounjaro and $1.9 billion for its obesity drug Zepbound.
Do Not Allow Advertisers to Use My Personal information
